Raphi Levy Sells 2,127 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,127 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $13.02, for a total value of $27,693.54. Following the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,174,143.60. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $13.23 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -19.75 and a beta of 1.17. The business has a 50-day simple moving average of $9.85 and a two-hundred day simple moving average of $7.89. Alpha Tau Medical Ltd. has a fifty-two week low of $2.87 and a fifty-two week high of $13.23.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on DRTS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Piper Sandler boosted their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. Barclays increased their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Zacks Research downgraded Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Finally, LADENBURG THALM/SH SH lifted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Alpha Tau Medical currently has an average rating of “Hold” and a consensus target price of $12.60.

Institutional Trading of Alpha Tau Medical

Several large investors have recently added to or reduced their stakes in the business. Trifecta Capital Advisors LLC purchased a new stake in Alpha Tau Medical during the fourth quarter valued at approximately $48,000. Envestnet Asset Management Inc. purchased a new position in shares of Alpha Tau Medical during the 3rd quarter worth $62,000. Bank of America Corp DE grew its position in shares of Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the period. Wells Fargo & Company MN grew its position in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after acquiring an additional 17,500 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical in the 1st quarter worth $132,000. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.